{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:01:43Z","timestamp":1789563703367,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA094056"],"award-info":[{"award-number":["P50 CA094056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA091842"],"award-info":[{"award-number":["P30 CA091842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR220088"],"award-info":[{"award-number":["RR220088"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00828-4","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T03:02:35Z","timestamp":1680836555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma"],"prefix":"10.1038","volume":"13","author":[{"given":"Mina","family":"Maksimos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Muz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2780","authenticated-orcid":false,"given":"Abdel Kareem","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"828_CR1","unstructured":"Cancer Stat Facts: Myeloma: National Cancer Institute; 2023 Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"828_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/CCO.0000000000000615","volume":"32","author":"OC Lomas","year":"2020","unstructured":"Lomas OC, Tahri S, Ghobrial IM. The microenvironment in myeloma. Curr Opin Oncol. 2020;32:170\u20135.","journal-title":"Curr Opin Oncol"},{"key":"828_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.18654","volume":"200","author":"D Minakata","year":"2023","unstructured":"Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, et al. Relapsed and refractory multiple myeloma: a systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol. 2023;200:694\u2013703.","journal-title":"Br J Haematol"},{"key":"828_CR4","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119:1468\u201378.","journal-title":"Blood"},{"key":"828_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ejh.12870","volume":"98","author":"P de la Puente","year":"2017","unstructured":"de la Puente P, Azab AK. Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma. Eur J Haematol. 2017;98:529\u201341.","journal-title":"Eur J Haematol"},{"key":"828_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jconrel.2017.11.045","volume":"270","author":"P de la Puente","year":"2017","unstructured":"de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, et al. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. J Control Release. 2017;270:158\u201376.","journal-title":"J Control Release"},{"key":"828_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19932-1","volume":"11","author":"C Federico","year":"2020","unstructured":"Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, et al. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun. 2020;11:6037.","journal-title":"Nat Commun"},{"key":"828_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/cancers13020335","volume":"13","author":"B Muz","year":"2021","unstructured":"Muz B, Abdelghafer A, Markovic M, Yavner J, Melam A, Salama NN, et al. Targeting E-selectin to tackle cancer using uproleselan. Cancers. 2021;13:335.","journal-title":"Cancers"},{"key":"828_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0227-3","volume":"9","author":"B Muz","year":"2019","unstructured":"Muz B, Azab F, Fiala M, King J, Kohnen D, Fogler WE, et al. Inhibition of E-selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy. Blood Cancer J. 2019;9:68.","journal-title":"Blood Cancer J"},{"key":"828_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/leu.2016.3","volume":"30","author":"M Moschetta","year":"2016","unstructured":"Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, et al. Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia. 2016;30:1103\u201315.","journal-title":"Leukemia"},{"key":"828_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","volume":"66","author":"AM Roccaro","year":"2006","unstructured":"Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66:184\u201391.","journal-title":"Cancer Res"},{"key":"828_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","volume":"73","author":"P de la Puente","year":"2015","unstructured":"de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, et al. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials. 2015;73:70\u201384.","journal-title":"Biomaterials"},{"key":"828_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood-2006-10-054502","volume":"110","author":"O Wagner-Ballon","year":"2007","unstructured":"Wagner-Ballon O, Pisani DF, Gastinne T, Tulliez M, Chaligne R, Lacout C, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood. 2007;110:345\u201353.","journal-title":"Blood"},{"key":"828_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jconrel.2017.11.045","volume":"270","author":"P de la Puente","year":"2018","unstructured":"de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, et al. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. J Control Release. 2018;270:158\u201376.","journal-title":"J Control Release"},{"key":"828_CR15","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1111\/bph.14063","volume":"174","author":"NA Duggett","year":"2017","unstructured":"Duggett NA, Flatters SJL. Characterization of a rat model of bortezomib-induced painful neuropathy. Br J Pharm. 2017;174:4812\u201325.","journal-title":"Br J Pharm"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00828-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00828-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00828-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T03:02:41Z","timestamp":1680836561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00828-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["828"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00828-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AKA received research funding to partially support this study from GlycoMimetics Inc. Moreover, AKA is the founder and owner of Targeted Therapeutics LLC and Cellatrix LLC; however, these have no contribution to this study. JLM is an employee and shareholder of GlycoMimetics Inc. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}